ѻý

PTSD Post-COVID; Caplyta Seeking New Indications

<ѻý class="mpt-content-deck">— News and commentary from the psychiatry world
MedpageToday
Illustration of a brain shaped maze.

Ten companies were for illegally selling supplements claiming to cure depression and other mental health disorders.

A survey of 381 patients found that more than 30% had post-traumatic stress disorder. (JAMA Psychiatry)

Intra-Cellular Therapies is formally seeking two new indications for its -- as monotherapy and as adjunctive therapy to lithium or valproate for depressive episodes of adult bipolar I or II disorder.

A meta-analysis of 12 studies and nearly two million participants found that was tied to an increased risk for developing a psychotic disorder. (JAMA Psychiatry)

Should those with mental health disorders cut the line? (Forbes)

NYU Langone Health in Manhattan announced the launch of a new under the department of psychiatry.

A phase IIa study is in the works to test an investigative , Tryp Therapeutics announced.

The FDA issued a warning letter to AcelRx Pharmaceuticals for misleading promotion of its potent opioid analgesic .

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.